TOPIC 396: NON-INVASIVE DETECTION OF HUMAN CD8+ T CELLS: A PET-BASED APPROACH TO ASSESS THE HUMAN IMMUNESYSTEM - MOONSHOT
TOPIC 396: NON-INVASIVE DETECTION OF HUMAN CD8+ T CELLS: A PET-BASED APPROACH TO ASSESS THE HUMAN IMMUNESYSTEM - MOONSHOT
批准号:
10044540
负责人:
KIERA CLAYTON
金额:
$29.87万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-16 至 2020-06-15
关键词:
BiopsyCD8-Positive T-LymphocytesCD8B1 geneChelating AgentsChemistryClinicalFoundationsHumanImmune systemImmunotherapyInfiltrationMalignant NeoplasmsMusNon-Invasive Cancer DetectionPositron-Emission TomographyProteinsRadioisotopesRadiolabeledReagentResearchScanningSiteTechnologyTherapeuticTranslationsValidationWorkbasehuman imaginghumanized mousein vivoindividualized medicineinnovative technologiesmouse modelnanobodiesoutcome forecastpre-clinicalpredicting responsestandard of caresuccesstraffickingtreatment responsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Immunotherapy has shown impressive success in treating several cancers, however, responses to treatment are variable, and predicting the response to therapy remains a major obstacle. Biopsy analyses has correlated good prognosis with infiltration of CD8+ T cells into the tumor and recent preclinical work suggests that tracking of CD8+ T cells in tumors using single domain antibody (VHH)–based PET imaging can accurately predict response to immunotherapy in mice. Furthermore, VHH PEGylation dramatically enhances the sensitivity of this PET imaging. The objectives of this research are to (1) create a VHH specific for human CD8, (2) develop a non-enzymatic, site-specific chemistry to allow for a GMP-scalable dual conjugation of the VHH to a PEG molecule and radioisotope, and (3) validate this reagent for PET-based imaging of human CD8+ T cell trafficking in a humanized mouse model. The successful completion of these objectives will provide the foundation for translation of this innovative technology to a clinical setting as a “CD8 Scan”, the first of its kind to non-invasively track the human immune system. This technology will become the next standard of care, used in conjunction with immunotherapy to rapidly assess responses to treatment and tailor treatment with the greatest therapeutic benefit.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金